CClinicalTrials.gg
SuspendedNCT06868238Updated Sep 11, 2026

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

A Phase 2 interventional study of Magtrace in Ductal Carcinoma in Situ, sponsored by University of Florida. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

Why this study was suspended
Major protocol revision involving eligibility criteria and screening procedures in progress
Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node biopsy (SLNB) procedure where the lymph nodes that drain the breast first are removed at the time of mastectomy. This recommendation for traditional SLNB is due to the risk of finding invasive cancer during surgical evaluation of the mastectomy specimen and the inability to accurately map the lymphatic channels once the breast is removed.

In a study by Herremans et al, the majority of traditional SLNBs were demonstrated to be unnecessary. By using Magtrace, a novel iron based lymphatic mapping agent, a delayed SLNB could eliminate these unnecessary traditional SLNBs.

Magtrace, or superparamagnetic oxide (SPIO), was developed in 2018. Unlike traditional mapping agents of blue dye and technetium that clear the body within 24-48 hours, Magtrace remains in the lymph nodes for at least 4 weeks. Magtrace's ability to remain in the lymph node allows accurate mapping of the lymph nodes at the time of the mastectomy with the ability to return to the operating room for a delayed sentinel lymph node biopsy if invasive cancer is found on final pathology.

This study will investigate whether the use of Magtrace will successfully allow patients with DCIS undergoing mastectomy to avoid undergoing SLNB.

02

Conditions studied

  • Ductal Carcinoma in Situ

Keywords

  • ductal carcinoma in situ
  • superparamagnetic oxide (SPIO/Magtrace)
  • sentinel lymph node biopsy
  • mastectomy
  • breast
  • lymphedema
03

In context

Carcinoma, Intraductal, Noninfiltrating

205 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 46 are open to participants now.

This study's planned enrollment of 30 is below the median of 69 across 155 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

University of Florida is the lead sponsor of 1,254 studies on the registry; 201 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 136 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults ≥ 18 years of age.
  • Patients with a core needle biopsy diagnosis consistent with ductal carcinoma in-situ (DCIS), Stage 0 breast cancer, who are planning to undergo a mastectomy.

    o The mastectomy can be with or without reconstruction and with or without contralateral prophylactic mastectomy.

  • Patients with a negative pre-operative axillary ultrasound.
  • For subjects of childbearing potential, a pregnancy test that has resulted as negative is required preoperatively.
  • Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with contralateral invasive breast cancer requiring traditional sentinel lymph node biopsy at time of index operation or additional chemotherapy that may have been omitted for DCIS.
  • Any history of receiving chemotherapy
  • Prior ipsilateral breast cancer with treatment that included radiation, lumpectomy, chemotherapy, or sentinel lymph node biopsy.
  • Ipsilateral prior axillary sentinel lymph node biopsy for other malignancy (i.e., melanoma).
  • Patients with a history of upper extremity blood clot, lymphangitis/cellulitis, lymphedema, or those who use a pacemaker device
  • Patients with an allergy to iron, dextran, or any other ingredient in Magtrace.
  • Patients with an abnormal pre-operative axillary ultrasound.
  • Subjects who are confirmed to be pregnant.
  • History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
  • Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Magtrace injection

    Drug: Magtrace

Interventions

  • DrugMagtrace

    Participants will receive a single injection of Magtrace into the breast during their mastectomy.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with DCIS who do not undergo sentinel lymph node biopsy

    Determine the percentage of patients with DCIS who do not undergo sentinel lymph node biopsy.

    Time frame: 24 months post-mastectomy

Secondary outcomes

  1. Percentage of patients that are found to have invasive disease at time of mastectomy

    Determine the Percentage of patients that are found to have invasive disease at time of mastectomy.

    Time frame: At the time of mastectomy

  2. Rate of return to operating room for delayed sentinel lymph node biopsy

    Determine the number of patients who return to the operating room for delayed sentinel lymph node biopsy.

    Time frame: 24 months post-mastectomy

  3. Patient-reported outcomes measures

    Compare the scores obtained to the historical control for each of the following scales of the Breast-Q questionnaire: psychosocial well-being, sexual well-being, cancer worry, fatigue, and impact on work.

    Time frame: 24 months post-mastectomy

07

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32608, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06868238
Lead sponsor
University of Florida
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Oct 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Sep 11, 2026

Study contacts

Lisa Spiguel, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion